Lincoln Pharmaceuticals Limited (NSE:LINCOLN)

Market Cap	12.28B +12.9%
Revenue (ttm)	6.71B +7.7%
Net Income	878.94M +6.7%
EPS	43.88 +6.7%
Shares Out	n/a
PE Ratio	13.97
Forward PE	n/a
Dividend	1.80 (0.30%)
Ex-Dividend Date	Sep 12, 2025

Volume	25,584
Open	618.00
Previous Close	608.75
Day's Range	611.10 - 622.90
52-Week Range	440.00 - 770.00
Beta	0.36
Analysts	Strong Buy
Price Target	322.00 (-47.61%)
Earnings Date	May 28, 2026

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 1,853
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LINCOLN

Financial Performance

In fiscal year 2026, Lincoln Pharmaceuticals's revenue was 6.71 billion, an increase of 7.67% compared to the previous year's 6.23 billion. Earnings were 878.94 million, an increase of 6.74%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error